Perrigo Company PLC banner

Perrigo Company PLC
SWB:PIG

Watchlist Manager
Perrigo Company PLC Logo
Perrigo Company PLC
SWB:PIG
Watchlist
Price: 9.092 EUR 12.03% Market Closed
Market Cap: €1.2B

P/FCFE

-15.2
Current
419%
Cheaper
vs 3-y average of 4.8

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-15.2
=
Market Cap
€1.5B
/
Free Cash Flow to Equity
$-107.9m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-15.2
=
Market Cap
€1.5B
/
Free Cash Flow to Equity
$-107.9m

Valuation Scenarios

Perrigo Company PLC is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (4.8), the stock would be worth €-2.85 (131% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-295%
Maximum Upside
No Upside Scenarios
Average Downside
187%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple -15.2 €9.09
0%
3-Year Average 4.8 €-2.85
-131%
5-Year Average 6 €-3.6
-140%
Industry Average 29.6 €-17.73
-295%
Country Average 12.6 €-7.53
-183%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
IE
Perrigo Company PLC
SWB:PIG
1.6B EUR -15.2 -1.2
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
IE
Perrigo Company PLC
SWB:PIG
Average P/E: 523.3
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

Lower than 100% of companies in Ireland
Percentile
0th
Based on 226 companies
0th percentile
-11.6
Low
0 — 5.5
Typical Range
5.5 — 22.8
High
22.8 —
Distribution Statistics
Ireland
Min 0
30th Percentile 5.5
Median 12.6
70th Percentile 22.8
Max 6 997.4

Perrigo Company PLC
Glance View

Perrigo Company PLC, a stalwart in the pharmaceutical and healthcare sectors, has carved a niche by specializing in over-the-counter (OTC) health and wellness products. This Dublin-based company traces its origins back to 1887, in Allegan, Michigan, where it began as a modest packager of home remedies. Over the decades, Perrigo has evolved into a global powerhouse that provides affordable and quality healthcare products, distributing them across various markets around the world. Its strategy hinges on delivering effective OTC solutions and a wide array of consumer self-care products, making it a familiar presence in households seeking reliable alternatives to more expensive brand-name pharmaceuticals. Perrigo's business model is centered on offering value to both consumers and retailers. By producing generic versions of well-known drugs, it captures a significant share of the market driven by cost-conscious customers. This approach also involves collaborating with retail giants to supply their private label OTC medications, a mutually beneficial arrangement that allows retailers to offer lower-cost alternatives under their own brands while maintaining healthy margins. Beyond just OTC medications, Perrigo has expanded its offerings to include nutritional products and topical solutions, further diversifying its portfolio and revenue streams. The company's consistent investment in innovation and keen attention to regulatory compliance underscore its commitment to quality and safety, attributes that resonate well in an industry guided by trust and efficacy.

PIG Intrinsic Value
51.661 EUR
Undervaluation 82%
Intrinsic Value
Price €9.092
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett